0B68 Eisenlohr, Laurence C. - Thomas Jefferson University - Thomas Jefferson University
lce101

Laurence C. Eisenlohr, VMD, PhD

Contact Dr. Eisenlohr

233 South Tenth Street
Bluemle Life Sciences Building, Room 730
Philadelphia, PA 19107

(215) 503-4540
(215) 923-4153 fax

Most Recent Peer-reviewed Publications

  1. MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve toll-like receptor 2
  2. Recombinant poxviruses: Versatile tools for immunological assays
  3. Toward a network model of MHC class II-restricted antigen processing
  4. Alternative generation of MHC class II-restricted epitopes: Not so exceptional?
  5. Comparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T Cells despite markedly different in vivo replication and pathogenicity
  6. Perforin-dependent CD4 + T-cell cytotoxicity contributes to control a murine poxvirus infection
  7. Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein
  8. Beyond the classical: Influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways
  9. Functional macroautophagy induction by influenza A virus without a contribution to major histocompatibility complex class II-restricted presentation
  10. Hydrophobicity as a driver of MHC class i antigen processing
  11. Cutting edge: Selective role of ubiquitin in MHC class I antigen presentation
  12. Exosome-driven antigen transfer for MHC class II presentation facilitated by the receptor binding activity of influenza hemagglutinin
  13. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis
  14. Lineage-specific T-cell responses to Cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease
  15. Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens
  16. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity
  17. Derivation and fluidity of acutely induced dysfunctional CD8 + T cells
  18. Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen
  19. Rethinking peptide supply to MHC class I molecules
  20. Oncogenic inflammation and autoimmune disease
0